

## SEQUENCE LISTING

<110> Otsuka Pharmaceutical Co., Ltd.

<120> A method for determining the risk of drug-induced agranulocytosis

<130> OP0046

<140>

<141>

<160> 17

<170> PatentIn Ver. 2.1

<210> 1

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 1

accactgtat ttgtgacaac tc

22

<210> 2

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 2

aaatatggat cagtctcttt cc

22

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 3

atgttcattt tatgagggag g

21

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 4

aactgccaat ccagagctgc

20

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 5  
tctcaccaca ccgcttcaag

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of  
Insulin receptor substance-2 (IRS-2)

<400> 6  
ccacattttc ttcaagcacc

20

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of  
Insulin receptor substance-2 (IRS-2)

<400> 7  
gagcttgctg ggatctgaac

20

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of

Insulin receptor substance-2 (IRS-2)

<400> 8

atgtgactcg gcgttacgca

20

<210> 9

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 9

ccttgacgtg gaagcatg

18

<210> 10

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 10

ctatcccgat tcctagatgt c

21

<210> 11

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 11

gactcatctg tgactaactc c

21

<210> 12

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 12

cctagatgtc agcttgccc

19

<210> 13

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 13

tctggaactc cagagattgc

20

<210> 14

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 14

tgctgagcgt cttcttttaa tggta

25

<210> 15

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 15

gaggcttttt tagaggaaga cc

22

<210> 16

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 16

catgtcatgg aggagcatt c

21

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 17

gcaaaagtct tcctgcttcc

20